Home Newsfeeds Craig-Hallum Upgrades Cerence to Buy, Announces $40 Price Target

Craig-Hallum Upgrades Cerence to Buy, Announces $40 Price Target

Craig-Hallum analyst Jeff Van Rhee upgrades Cerence (NASDAQ:CRNC) from Hold to Buy and announces $40 price target.

byBenzinga Newsdesk

February 9, 2023

1 minute read

Craig-Hallum analyst Jeff Van Rhee upgrades Cerence (NASDAQ:CRNC) from Hold to Buy and announces $40 price target.

Dollar Tree Gets Price Target Cuts By Analysts After Q1 Results

By Lisa Levin

May 26, 7:07 AM

Dollar Tree Inc (NASDAQ: DLTR) reported mixed first-quarter financial results and issued guidance.

DLTR

Movers
News

What’s Going On With AMC Entertainment Stock Wednesday?

By Adam Eckert

April 17, 9:24 AM

AMC shares are down more than 99% below their all-time highs. The selloff in AMC stock accelerated at the end of March after the company announced an at-the-market offering program to sell up to $250 million of its common stock from time to time.

AMC

BridgeBio Pharma Announces Results Of Five New Analyses Of Clinical Endpoints From Phase 3 ATTRibute-CM Study of Acoramidis In ATTR-CM At ISA

By Benzinga Newsdesk

May 29, 4:03 PM

- Acoramidis treatment resulted in increased serum transthyretin (TTR) levels by Day 28 that were sustained and were correlated with a reduced risk of all-cause mortality (ACM), cardiovascular mortality (CVM), and

BBIO

Paysafe Q3 EPS $0.00 Vs. $(0.20) YoY, Sales $366.00M Beat $355.94M Estimate

By Benzinga Newsdesk

November 10, 7:56 AM

Paysafe (NYSE:PSFE) reported quarterly sales of $366.00 million which beat the analyst consensus estimate of $355.94 million by 2.83 percent. This is a 3.51 percent increase over sales of $353.58 million the same period

PSFE

Craig-Hallum Upgrades Cerence to Buy, Announces $40 Price Target

Related Posts

Dollar Tree Gets Price Target Cuts By Analysts After Q1 Results

What’s Going On With AMC Entertainment Stock Wednesday?

BridgeBio Pharma Announces Results Of Five New Analyses Of Clinical Endpoints From Phase 3 ATTRibute-CM Study of Acoramidis In ATTR-CM At ISA

Paysafe Q3 EPS $0.00 Vs. $(0.20) YoY, Sales $366.00M Beat $355.94M Estimate